TY - JOUR

T1 - Prognostic molecular markers in pediatric liver disease - Are there any?

AU - Nielsen, Jon

AU - Christensen, Vibeke Brix

AU - Borgwardt, Lise

AU - Rasmussen, Allan

AU - Østrup, Olga

AU - Kjær, Mette Skalshøi

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Pediatric liver disease (PLD) is a major cause of severe morbidity and prolonged hospitalizations in children. Stratifying patients in terms of prognosis remains challenging. The limited knowledge about molecular mechanisms causing and accompanying PLD remains the main obstacle in a search for reliable prognostic biomarkers. A systematic search of MEDLINE via PubMed and Embase via OVID was conducted on studies published between August 2007 and August 2017. Molecular markers with a prognostic potential in terms of survival, need for liver transplantation or disease progression/regression were selected. In general, identified studies were single center smaller case-control studies or case series with a low level of evidence and a high risk of bias. Only 23 studies comprising 898 patients could be included, mostly focusing on biliary atresia, non-alcoholic fatty liver disease, viral hepatitis, and LT; and markers related to morphogenesis and fibrosis. Furthermore, molecular markers in metabolic pathways and inflammation shown to be relevant, however requiring further validation. Hence, further biological and clinical studies are needed to gain greater molecular insight into PLD.

AB - Pediatric liver disease (PLD) is a major cause of severe morbidity and prolonged hospitalizations in children. Stratifying patients in terms of prognosis remains challenging. The limited knowledge about molecular mechanisms causing and accompanying PLD remains the main obstacle in a search for reliable prognostic biomarkers. A systematic search of MEDLINE via PubMed and Embase via OVID was conducted on studies published between August 2007 and August 2017. Molecular markers with a prognostic potential in terms of survival, need for liver transplantation or disease progression/regression were selected. In general, identified studies were single center smaller case-control studies or case series with a low level of evidence and a high risk of bias. Only 23 studies comprising 898 patients could be included, mostly focusing on biliary atresia, non-alcoholic fatty liver disease, viral hepatitis, and LT; and markers related to morphogenesis and fibrosis. Furthermore, molecular markers in metabolic pathways and inflammation shown to be relevant, however requiring further validation. Hence, further biological and clinical studies are needed to gain greater molecular insight into PLD.

KW - Age of Onset

KW - Biomarkers/analysis

KW - Case-Control Studies

KW - Child

KW - Disease Progression

KW - Humans

KW - Liver Diseases/diagnosis

KW - Non-alcoholic Fatty Liver Disease/diagnosis

KW - Prognosis

U2 - 10.1016/j.bbadis.2018.12.018

DO - 10.1016/j.bbadis.2018.12.018

M3 - Review

VL - 1865

SP - 577

EP - 586

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 3

ER -